| |
CVD-PCSK9 Repatha Outcomes Study FOURIER
|
| |
| |
Evolocumab - FOURIER Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (05/02/17)
The FOURIER trial shows that evolocumab, which is a fully human monoclonal antibody against PCSK9, causes a significant reduction of 15% in the primary end-points of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; in addition, it also causes a significant reduction of 20% in some secondary end-points of cardiovascular death, myocardial infarction, or stroke. Notably, the benefit was driven by reductions in the incidence of nonfatal AMI, stroke, and coronary revascularization, but the incidence of cardiovascular (CV) death remained similar in both groups. However, it is important to note that cost issues were of concern even in the USA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469080/
2 New HIV CVD/Heart Disease Drugs: PCSK9 inhibitor & 1st CVD Anti-Inflammatory Canakinumab - (07/10/17)
1st CVD Anti-InflammatoryCanakinumab with Positive Phase 3 Results Announced - Studied in HIV at CROI - (06/26/17)
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia - (07/19/17)
Statin (JUPITER study) in Elderly with Relatively Low Risk Factors - (05/25/17)
Study Casts Doubt on Need for Statins in the 'Healthy Old' - But specialists cite research flaws, limitations - (05/25/17)
Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization [from Jules: relatively low risk] - (05/25/17)
Statins effects in Older Adults Risks/Benefits - Primary Prevention / ALLHAT-LLT Study "patients without atherosclerotic cardiovascular disease" - (05/25/17)
Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines - new analysis: "the evidence is lacking for older adults without major cardiovascular risk aside from age" - (05/25/17)
|
|
| |
| |
|
|
|
